AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18332760 — intervention group
Group type: COMPARATOR
Intervention: Ball attachment
Number of subjects: 26
Study 16515109 — intervention group
Group type: EXPERIMENTAL
Intervention: Human amniotic membrane
Number of subjects: 50
Study 16515109 — intervention group
Group type: COMPARATOR
Intervention: Temporalis fascia
Number of subjects: 50
Study 12439775 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased training over 4 days
Number of subjects: 12
Study 10416915 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirilazad mesylate (3 mg/kg for men, 3.75 mg/kg for women)
Number of subjects: 20
Study 10416915 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 20
Study 7501338 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous sumatriptan
Number of subjects: 179
Study 7501338 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study 2360920 — intervention group
Group type: EXPERIMENTAL
Intervention: One‐year exercise program
Number of subjects: 79
Study 2360920 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control condition
Number of subjects: 79
Study 2360920 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline data and one‐year change data
Number of subjects: 79
Study 2360920 — intervention group
Group type: EXPERIMENTAL
Intervention: Total cholesterol
Number of subjects: 79
Study 113838 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmethylimipramine (DMI), 5 mg/kg, administered intramuscularly daily during the second separation.
Number of subjects: 7
Study 113838 — intervention group
Group type: COMPARATOR
Intervention: Control group (no DMI treatment) during the second separation.
Number of subjects: 7
Study 6408235 — intervention group
Group type: EXPERIMENTAL
Intervention: Cereal
Number of subjects: 16
Study 6408235 — intervention group
Group type: COMPARATOR
Intervention: Glucose polymers
Number of subjects: 16
Study 6408235 — intervention group
Group type: COMPARATOR
Intervention: Glucose
Number of subjects: 16
Study 30917842 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant gemcitabine plus nab-paclitaxel
Number of subjects: 0
Study 30917842 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant gemcitabine plus nab-paclitaxel with SBRT
Number of subjects: 0
Study 30917842 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant S-1 plus nab-paclitaxel with SBRT
Number of subjects: 0
Study 29402332 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trimoxazole 480 mg (two tablets) twice daily for a median treatment period of 27 months (range 12-42 months)
Number of subjects: 330
Study 29402332 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two tablets) twice daily for a median treatment period of 27 months (range 12-42 months)
Number of subjects: 330
Study 29402332 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trimoxazole
Number of subjects: 330
Study 24165306 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutting diathermy
Number of subjects: 31
Study 24165306 — intervention group
Group type: COMPARATOR
Intervention: Scalpel
Number of subjects: 31
Study 24165306 — intervention group
Group type: COMPARATOR
Intervention: Photographed wounds assessed by surgeons
Number of subjects: 31
Study 24203065 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (T)
Number of subjects: 24
Study 24203065 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone
Number of subjects: 24
Study 24203065 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol
Number of subjects: 24
Study 24203065 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 24
Study 23062189 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (150 mg/day increasing to 300 or 450 mg/day)
Number of subjects: 498
Study 23062189 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 498
Study 20680680 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin plus paclitaxel (ET)
Number of subjects: 287
Study 20680680 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin, paclitaxel and capecitabine (TEX)
Number of subjects: 287
Study 17953762 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin cream treatment
Number of subjects: 9025
Study 16087950 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF-Z (CAF followed by 5 years of monthly goserelin)
Number of subjects: 1503
Study 16087950 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF-ZT (CAF followed by 5 years of monthly goserelin and daily tamoxifen)
Number of subjects: 1503
Study 16087950 — intervention group
Group type: COMPARATOR
Intervention: CAF (six cycles of cyclophosphamide, doxorubicin, and fluorouracil)
Number of subjects: 1503
Study 12198267 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette advertisement (Benson & Hedges)
Number of subjects: 100
Study 12198267 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette advertisement (Marlboro)
Number of subjects: 100
Study 12198267 — intervention group
Group type: COMPARATOR
Intervention: Photograph of a packet of cigarettes (Control)
Number of subjects: 100
Study 9617725 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryo/Cuff with continuous circulating ice water (Group 1)
Number of subjects: 78
Study 9617725 — intervention group
Group type: COMPARATOR
Intervention: Cryo/Cuff with room temperature water (Group 2)
Number of subjects: 78
Study 7663592 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal temperature measurement
Number of subjects: 13
Study 7663592 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral temperature measurement
Number of subjects: 13
Study 7663592 — intervention group
Group type: EXPERIMENTAL
Intervention: Ear-based temperature measurement
Number of subjects: 13
Study 7663592 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary temperature measurement
Number of subjects: 13
Study 7663592 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral or ear-based temperatures
Number of subjects: 13
Study 2630344 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocapsular cataract extraction
Number of subjects: 176
Study 2630344 — intervention group
Group type: COMPARATOR
Intervention: Standard extracapsular procedure
Number of subjects: 176
Study 909754 — intervention group
Group type: EXPERIMENTAL
Intervention: High doses of metenolone during MOPP chemotherapy
Number of subjects: 32
Study 909754 — intervention group
Group type: COMPARATOR
Intervention: MOPP chemotherapy without androgenotherapy (implied control)
Number of subjects: 32
Study 31793398 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium-Olodaterol combination
Number of subjects: 0
Study 31793398 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium alone
Number of subjects: 0
Study 31161202 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation therapy (intervention relaxation group)
Number of subjects: 64
Study 27646197 — intervention group
Group type: EXPERIMENTAL
Intervention: L-DOPA
Number of subjects: 85
Study 27646197 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 27646197 — intervention group
Group type: EXPERIMENTAL
Intervention: L-DOPA and Placebo
Number of subjects: 85
Study 25964034 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal scrubber
Number of subjects: 30
Study 25964034 — intervention group
Group type: EXPERIMENTAL
Intervention: Partly-failed scrubber
Number of subjects: 30
Study 25964034 — intervention group
Group type: EXPERIMENTAL
Intervention: Absent scrubber
Number of subjects: 30
Study 22716932 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid Deprivation (FD)
Number of subjects: 20
Study 22716932 — intervention group
Group type: COMPARATOR
Intervention: Fully hydrated control condition
Number of subjects: 20
Study 21284549 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive non-surgical technique (MINST)
Number of subjects: 29
Study 21284549 — intervention group
Group type: COMPARATOR
Intervention: Minimally invasive surgical technique (MIST)
Number of subjects: 29
Study 21284549 — intervention group
Group type: COMPARATOR
Intervention: MIST
Number of subjects: 29
Study 21284549 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient perception of discomfort/pain and satisfaction
Number of subjects: 29
Study 19407262 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct switch from subcutaneous rHuEPO to intravenous darbepoetin (group 1)
Number of subjects: 154
Study 19407262 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect switch from subcutaneous rHuEPO to intravenous darbepoetin after 2 months of subcutaneous darbepoetin (group 2)
Number of subjects: 154
Study 19407262 — intervention group
Group type: COMPARATOR
Intervention: Intravenous rHuEPO switched to intravenous darbepoetin (control group)
Number of subjects: 154
Study 17385588 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral transmucosal fentanyl citrate (OTFC)
Number of subjects: 9
Study 17385588 — intervention group
Group type: COMPARATOR
Intervention: Entonox plus placebo
Number of subjects: 9
Study 15459145 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral levofloxacin
Number of subjects: 129
Study 15459145 — intervention group
Group type: COMPARATOR
Intervention: Sequential antibiotic treatment
Number of subjects: 129
Study 11003192 — intervention group
Group type: EXPERIMENTAL
Intervention: Face guard helmets provided to intervention teams
Number of subjects: 238
Study 11003192 — intervention group
Group type: COMPARATOR
Intervention: No face guard helmets (comparison teams)
Number of subjects: 238
Study 8994895 — intervention group
Group type: EXPERIMENTAL
Intervention: E‐BEHAVE‐AD rating scale
Number of subjects: 49
Study 1449389 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastroduodenoanastomosis for gastric drainage
Number of subjects: 60
Study 1449389 — intervention group
Group type: COMPARATOR
Intervention: Duodenum plasty (drainage of the duodenum)
Number of subjects: 60
Study 2869574 — intervention group
Group type: EXPERIMENTAL
Intervention: terbutaline (beta‐2 agonist)
Number of subjects: 12
Study 2869574 — intervention group
Group type: EXPERIMENTAL
Intervention: prenalterol (beta‐1 agonist)
Number of subjects: 12
Study 2869574 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 2869574 — intervention group
Group type: EXPERIMENTAL
Intervention: OP‐CCK (sincalide), 80 ng X kg‐1 X h‐1
Number of subjects: 12
Study 30527839 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilaprisan 0.5 mg
Number of subjects: 300
Study 30527839 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilaprisan 1.0 mg
Number of subjects: 300
Study 30527839 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilaprisan 2.0 mg
Number of subjects: 300
Study 30527839 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilaprisan 4.0 mg
Number of subjects: 300
Study 30527839 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 30527839 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilaprisan (≥1.0 mg)
Number of subjects: 300
Study 30527839 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilaprisan
Number of subjects: 300
Study 29952886 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative-pressure fixation
Number of subjects: 13
Study 29952886 — intervention group
Group type: COMPARATOR
Intervention: Film dressing
Number of subjects: 13
Study 26848792 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week dose reduction group
Number of subjects: 374
Study 26848792 — intervention group
Group type: EXPERIMENTAL
Intervention: 26-week dose reduction group
Number of subjects: 374
Study 26848792 — intervention group
Group type: COMPARATOR
Intervention: No-dose-reduction group
Number of subjects: 374
Study 26215396 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein (HP) diet (5 g · kg(‐1) · d(‐1))
Number of subjects: 28
Study 26215396 — intervention group
Group type: COMPARATOR
Intervention: Normal protein (NP) diet (2 g · kg(‐1) · d(‐1))
Number of subjects: 28
Study 23800880 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate exercise (300 kcal/day)
Number of subjects: 61
Study 23800880 — intervention group
Group type: EXPERIMENTAL
Intervention: High exercise (600 kcal/day)
Number of subjects: 61
Study 23800880 — intervention group
Group type: COMPARATOR
Intervention: Sedentary living (Control)
Number of subjects: 61
Study 23800880 — intervention group
Group type: EXPERIMENTAL
Intervention: Both exercise groups (Moderate and High)
Number of subjects: 61
Study 20939639 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intention-only condition
Number of subjects: 4391
Study 20939639 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intention conditions
Number of subjects: 4391
Study 20939639 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intentions
Number of subjects: 4391
Study 20939639 — intervention group
Group type: EXPERIMENTAL
Intervention: Measuring anticipated regret
Number of subjects: 4391
Study 20939639 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaire completion
Number of subjects: 4391
Study 20939639 — intervention group
Group type: COMPARATOR
Intervention: No-questionnaire control condition
Number of subjects: 4391
Study 19020157 — intervention group
Group type: COMPARATOR
Intervention: Tapentadol HCl 50 mg
Number of subjects: 400
Study 19020157 — intervention group
Group type: COMPARATOR
Intervention: Tapentadol HCl 75 mg
Number of subjects: 400
Study 19020157 — intervention group
Group type: COMPARATOR
Intervention: Tapentadol HCl 100 mg
Number of subjects: 400
Study 19020157 — intervention group
Group type: COMPARATOR
Intervention: Tapentadol HCl 200 mg
Number of subjects: 400
Study 19020157 — intervention group
Group type: COMPARATOR
Intervention: Morphine sulfate 60 mg
Number of subjects: 400
Study 19020157 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 400 mg
Number of subjects: 400
Study 19020157 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of tapentadol HCl
Number of subjects: 400
Study 16635169 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% glucose solution
Number of subjects: 25
Study 16635169 — intervention group
Group type: COMPARATOR
Intervention: Sterile water (placebo)
Number of subjects: 25
Study 14668074 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Smoking Control Index (policy in effect)
Number of subjects: 325
Study 14668074 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of policy at 6 and 12 months
Number of subjects: 325
Study 10945011 — intervention group
Group type: COMPARATOR
Intervention: BH-AC-DM (daunorubicin, behenoyl cytarabine, 6-mercaptopurine)
Number of subjects: 655
Study 10945011 — intervention group
Group type: EXPERIMENTAL
Intervention: BH-AC-EDM (daunorubicin, behenoyl cytarabine, 6-mercaptopurine, etoposide)
Number of subjects: 655
Study 10945011 — intervention group
Group type: COMPARATOR
Intervention: BH-AC-DM
Number of subjects: 655
Study 10945011 — intervention group
Group type: EXPERIMENTAL
Intervention: BH-AC-EDM
Number of subjects: 655
Study 8781610 — intervention group
Group type: EXPERIMENTAL
Intervention: Microemulsion formulation of cyclosporine (CsA)
Number of subjects: 6
Study 8781610 — intervention group
Group type: COMPARATOR
Intervention: Standard formulation of cyclosporine (CsA)
Number of subjects: 6
Study 1740900 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% Lipovenös
Number of subjects: 40
Study 1740900 — intervention group
Group type: COMPARATOR
Intervention: 20% Lipovenös
Number of subjects: 40
Study 6399891 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimetophrine 400 mg twice daily
Number of subjects: 30
Study 6399891 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 31270544 — intervention group
Group type: EXPERIMENTAL
Intervention: Late mid-sleep corrected for sleep debt (MSFsc)
Number of subjects: 2936
Study 31270544 — intervention group
Group type: EXPERIMENTAL
Intervention: Late sleep-onset time
Number of subjects: 2936
Study 31270544 — intervention group
Group type: EXPERIMENTAL
Intervention: Indication of Delayed Sleep Phase Syndrome (DSPS)
Number of subjects: 2936
Study 31270544 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately late chronotype in adulthood
Number of subjects: 2936
Study 31270544 — intervention group
Group type: COMPARATOR
Intervention: Extremely early chronotype
Number of subjects: 2936
Study 29117442 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip flexion training
Number of subjects: 37
Study 29117442 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee extension training
Number of subjects: 37
Study 29117442 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 37
Study 27175451 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodentine
Number of subjects: 37
Study 27175451 — intervention group
Group type: COMPARATOR
Intervention: Formocresol
Number of subjects: 37
Study 25543423 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint catgut embedding
Number of subjects: 33
Study 25543423 — intervention group
Group type: COMPARATOR
Intervention: Kuntai capsule
Number of subjects: 33
Study 22273648 — intervention group
Group type: EXPERIMENTAL
Intervention: Monopolar microdissection needle
Number of subjects: 1419
Study 22273648 — intervention group
Group type: COMPARATOR
Intervention: Cold dissection
Number of subjects: 1419
Study 20427729 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D(3) fortified orange juice (1000 IU)
Number of subjects: 60
Study 20427729 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D(2) fortified orange juice (1000 IU)
Number of subjects: 60
Study 20427729 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D supplements (1000 IU of either D(2) or D(3))
Number of subjects: 60
Study 20427729 — intervention group
Group type: COMPARATOR
Intervention: Placebo (orange juice or capsule)
Number of subjects: 60
Study 18669811 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist intervention
Number of subjects: 77
Study 18669811 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported adherence
Number of subjects: 77
Study 16248239 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified huanglian wendan decoction (MHWD) plus Xinkang tablet (XKT) 20 mg, twice a day for 1 month
Number of subjects: 90
Study 16248239 — intervention group
Group type: COMPARATOR
Intervention: Xinkang tablet (XKT) 20 mg, twice a day for 1 month
Number of subjects: 90
Study 14708444 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 75
Study 14708444 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 75
Study 14708444 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (ACE inhibitors and verapamil)
Number of subjects: 75
Study 14708444 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antihypertensive therapy)
Number of subjects: 75
Study 10365612 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam-ketamine
Number of subjects: 60
Study 10365612 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-ketamine
Number of subjects: 60
Study 10365612 — intervention group
Group type: COMPARATOR
Intervention: Propofol-fentanyl
Number of subjects: 60
Study 8145430 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (corinfar), 15‐80 mg daily for 12 weeks
Number of subjects: 25
Study 8145430 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (triampur), 25‐100 mg daily for 12 weeks
Number of subjects: 25
Study 8145430 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 27758064 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity aerobic exercise (25% peak oxygen uptake)
Number of subjects: 10
Study 27758064 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic exercise (65% peak oxygen uptake)
Number of subjects: 10
Study 25560678 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil-based lipid emulsion (OO)
Number of subjects: 103
Study 25560678 — intervention group
Group type: COMPARATOR
Intervention: Soybean oil-based lipid emulsion (SO)
Number of subjects: 103
Study 25560678 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (OO and SO)
Number of subjects: 103
Study 26434885 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous gemcitabine/cisplatin regimen plus daily oral metformin 500 mg (arm A)
Number of subjects: 30
Study 26434885 — intervention group
Group type: COMPARATOR
Intervention: Intravenous gemcitabine/cisplatin regimen alone (arm B)
Number of subjects: 30
Study 22209967 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Adiposity Index (BAI)
Number of subjects: 132
Study 22209967 — intervention group
Group type: COMPARATOR
Intervention: Dual-energy X-ray absorptiometry (DXA)
Number of subjects: 132
Study 22209967 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss intervention (calorie-restricted diet with or without resistance training)
Number of subjects: 132
Study 22209967 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiometabolic risk factors
Number of subjects: 132
Study 21813010 — intervention group
Group type: EXPERIMENTAL
Intervention: ADAPT robotic task‐practice system
Number of subjects: 5
Study 18998173 — intervention group
Group type: EXPERIMENTAL
Intervention: QuiXfil (Xeno III)
Number of subjects: 43
Study 18998173 — intervention group
Group type: COMPARATOR
Intervention: Tetric Ceram (Syntac Classic)
Number of subjects: 43
Study 16428533 — intervention group
Group type: EXPERIMENTAL
Intervention: ProSeal LMA (PLMA)
Number of subjects: 30
Study 16428533 — intervention group
Group type: COMPARATOR
Intervention: Classic laryngeal mask airway (CLMA)
Number of subjects: 30
Study 14574513 — intervention group
Group type: EXPERIMENTAL
Intervention: AC PET imaging
Number of subjects: 23
Study 14574513 — intervention group
Group type: COMPARATOR
Intervention: FDG PET imaging
Number of subjects: 23
Study 14574513 — intervention group
Group type: COMPARATOR
Intervention: MIBI SPET imaging
Number of subjects: 23
Study 11710962 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ)
Number of subjects: 21
Study 11710962 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 21
Study 10432881 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative for malignancy FNAB
Number of subjects: 1181
Study 7851306 — intervention group
Group type: EXPERIMENTAL
Intervention: Manually expressed breast milk
Number of subjects: 30
Study 7851306 — intervention group
Group type: COMPARATOR
Intervention: Pump expressed breast milk
Number of subjects: 30
Study 2790538 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus Injection (BI) of recombinant interleukin-2 (IL-2) at a maximum tolerated dose of 3 X 10(6) U/m2 per day for 7 days
Number of subjects: 25